Get Critical Health Info

Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

| More

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

This study is open to:
  • Men with advanced prostate cancer
  • Must have undergone surgical or medical castration (testosterone ≤ 50 ng/dL )
  • Disease progressed after receiving the following treatments for castration-resistant disease:
    • at least 1, but no more than 2 prior "next-generation androgen receptor-targeted therapies" (for example: Enzalutamide, also known as Xtandi or Abiraterone, also known Zytiga)
    • 1 prior taxane-based chemotherapy
    • Have a mutation in BRCA1 or BRCA2 or ATM, or molecular evidence of another mutation that causes homologous recombination deficiency
This study is not open to:

Patients will be excluded if they have:

  • any active second cancer diagnosis, with the exception of non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
  • prior treatment with a PARP inhibitor, mitoxantrone, cyclophosphamide or platinum-based chemotherapy
  • symptomatic and/or untreated central nervous system metastases
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

TRITON2 - Rucaparib for Castration Resistant Prostate Cancer

Clinicaltrials.gov identifier:
NCT02952534

Treatment:
Prostate

Study Contact Information

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

The study is open and recruiting at 21 sites, most in the US. 

United States Sites:

California: Los Angeles, San Diego, San Francisco, Santa Rosa; District of ColumbiaFlorida: Boca Raton, Orlando, Tampa; Georgia: Atlanta; Illinois: Chicago; Maryland: Baltomore; Michigan: Detroit; Missouri: Kansas City; Nebraska: Omaha; Nevada: Las Vegas; New Jersey: Township; New York: New York City, Poughkeepsie; Ohio: Middleburg Heights

United Kingdon Site

  • Liverpool, England

About the Study

Triton2 is a clinical trial for men with metastatic castration-resistant prostate cancer (prostate cancer that has spread to other organs and no longer responds to standard therapy), who have certain tumor markers and/or a mutation in the BRCA1, BRCA2 or ATM gene. Triton2 is looking at the effect of the PARP inhibitor Rucaparib (Rubraca) on delaying cancer progression in these men. 

All men who participate in the study will receive the study agent, Rucaparib

Type of Study

This is a three-arm, non-randomizedopen-label study.

  • This study has 3 arms, which means that patients will be assigned into three different groups.
  • The study is non-randomized, meaning that patients will be assigned to one of three groups based on specifics of their cancer.
    • Group A will include men with measurable disease (their cancer can be measured by tests or scans) who have a mutation in one of the following genes:
      • BRCA1
      • BRCA2
      • ATM
    • Group B will include men with no measurable disease (their cancer is in remission) who have a mutation in one of the following genes:
      • BRCA1
      • BRCA2
      • ATM
    • Group C will include men with or without measurable disease who have a different mutation that is associated with sensitivity to PARP inhibitors
      • BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51
  • The study is open-label. All participating patients will receive the study agent and will know which group they will be assigned to.  

What Study Entails

  • Patients with a known mutation in one of the above genes will not require additional prescreening. Patients who have not had a tumor or blood test for a mutation will be eligible for prescreening to see if they qualify. 
  • Patients will receive the oral PARP inhibitor Rucaparib (Rubraca) twice daily for 28 days.
  • Patients will receive followup at 28 days.
  • Patients will receive assessments every 8 weeks until week 24, then every 12 weeks.  
  • Patients who receive benefit from the drug may be considered for continued treatment. 
  • Patients whose cancer progresses will be taken off the study.

Study Sites

  • United States Sites:
    • California: 
      • Los Angeles
      • San Diego
      • San Francisco
      • Santa Rosa
    • District of Columbia
    • Florida: 
      • Boca Raton
      • Orlando
      • Tampa
    • Georgia:
      • Atlanta 
    • Illinois:
      • Chicago
    • Maryland:
      • Baltomore
    • Michigan:
      • Detroit
    • Missouri:
      • Kansas City
    • Nebraska:
      • Omaha
    • Nevada:
      • Las Vegas
    • New Jersey: 
      • Township 
    • New York:
      • New York City
      • Poughkeepsie 
    • Ohio:
      • Middleburg Heights

United Kingdon Site

  • Liverpool, England

FORCE:Facing Our Risk of Cancer Empowered